Overexpression of PRC1 indicates a poor prognosis in ovarian cancer

HUALEI BU1,2*, YINGWEI LI3*, CHENGJUAN JIN4, HONGFENG YU5, XIANGXIANG WANG1,2, JINGYING CHEN1,2, YU WANG1,2, YANA MA1,2, YOUSHONG ZHANG1,2 and BEIHUA KONG1,2

1Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University; 2Key Laboratory of Gynecologic Oncology of Shandong Province; 3School of Medicine, Shandong University, Jinan, Shandong 250012; 4Department of Obstetrics and Gynecology, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 201620; 5Department of Obstetrics and Gynecology, Zhenjiang First People's Hospital, Zhenjiang, Jiangsu 212000, P.R. China

Received May 19, 2019; Accepted November 11, 2019

DOI: 10.3892/ijo.2020.4959

Abstract. Protein regulator of cytokinesis-1 (PRC1) is a microtubule-associated factor involved in cytokinesis. Recent studies have indicated that PRC1 overexpression is involved in tumorigenesis in multiple types of human cancer. However, the expression, biological functions and the prognostic significance of PRC1 in ovarian cancer have not yet been clarified. In this study, it was confirmed that the PRC1 mRNA and protein expression levels were upregulated in high-grade serous ovarian carcinoma (HGSOC) tissues, particularly in patients without breast cancer susceptibility gene (BRCA) pathogenic mutations. PRC1 overexpression contributed to drug resistance, tumor recurrence and a poor prognosis. The findings also indicated that PRC1 knockdown decreased the proliferation, metastasis and multidrug resistance of ovarian cancer cells in vitro. It was also demonstrated that forkhead box protein M1 (FOXM1) regulated the mRNA and protein expression of PRC1. Dual-luciferase reporter assay and rescue assay confirmed that PRC1 was a direct crucial downstream target of FOXM1. On the whole, the findings of this study confirmed that PRC1 was a major prognostic factor of HGSOC and a promising therapeutic biomarker for the treatment of ovarian cancer.

Introduction

Epithelial ovarian cancer is a fatal gynecological malignancy, resulting in 295,414 new cases and 184,799 deaths worldwide in 2018 (1), exhibiting an upward trend (1,2). High-grade serous ovarian carcinoma (HGSOC) is the most common subtype (70%) associated with a higher degree of malignancy and a poorer prognosis (3). However, the molecular pathogenesis, the mechanisms of molecular regulation and drug resistance associated with HGSOC remain poorly characterized.

Protein regulator of cytokinesis-1 (PRC1), also known as Ase1 (yeast)/MAP65 (plant), was first identified as a CDK substrate in 1998 and was known as an essential microtubule associated protein required for cytokinesis via the phosphorylation of CDK1 (Cdc2/cyclin B) in early mitosis (4,5). Previous studies have found that cells in which PRC1 is knocked down can normally undergo interphase, prophase, prometaphase and metaphase, and chromatin can be equally distributed in the anaphase of mitosis; however, the structure of the central area of the spindle appears to be abnormal at anaphase, leading to the aberrant expression of cytokines and the formation of binuclear or multinucleated cells (5,6). Therefore, an abnormal expression of PRC1 can lead to aberrant cytokine expression, contributing to tumorigenesis and tumor progression.

It has already been demonstrated that PRC1 is upregulated in various types of tumor, such as hepatocellular carcinoma (7), gastric carcinoma (8) and pulmonary adenocarcinoma (9,10). The overexpression of PRC1 has been shown to significantly promoted the proliferation and metastasis of hepatocellular carcinoma cells, and to be associated with early recurrence and a poor patient outcome by regulating the oncogenic effects of the Wnt signaling pathway (7). The knockdown of PRC1 has also been shown to significantly suppress the proliferation, reduce monolayer colony formation and to inhibit the invasive and migratory ability of gastric carcinoma cells (8). To date, however, at least to the best of our knowledge, the expression, biological functions and prognosis significance of PRC1 in ovarian cancer have not yet been elucidated.

Correspondence to: Dr Youzhong Zhang or Dr Beihua Kong, Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, 107 Wenhua Xi Road, Jinan, Shandong 250012, P.R. China
E-mail: zhangyouzhong@vip.sina.com
E-mail: kongbeihua@sdu.edu.cn

*Contributed equally

Key words: protein regulator of cytokinesis-1, prognosis, drug resistance, breast cancer susceptibility gene, high-grade serous ovarian carcinoma

Overexpression of PRC1 indicates a poor prognosis in ovarian cancer
Materials and methods

Patients and tissue samples. All evaluated HGSOC and fallopian tube (FT) tissues were collected from the Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University from 2006 to 2016. The 4 μm tissue microarrays (TMAs), including 210 cases of HGSOC and 42 normal FT tissues, were designed in our laboratory. Fresh tissues of 28 cases of HGSOC and 14 normal FT tissues were also collected. Moreover, 18 specimens with chemosensitivity information for second-line chemotherapy were obtained from the specimen library. HGSOC tissues were obtained from patients who underwent primary surgery and no neo-adjuvant chemotherapy was performed. The normal FT tissues were obtained from patients who received hysterectomy and salpingo-oophorectomies due to benign disease. The clinicopathological characteristics of the patients are presented in Table I. The accurate assessment of the disease response was based on RECIST or GCIG standards (11). Ethics approval was obtained from the Ethics Committee of Shandong University, and written informed consent was obtained from each patient.

Cell lines and cell culture. The A2780 human ovarian cancer cell line was originally established from the tumor tissue of an untreated patient, and the cells grew as a monolayer and in suspension in spinner cultures. The SKOV3 cell line was originally isolated from the ascites of patients with ovarian tumors, and tumorigenesis in nude mice resulted in a moderately differentiated adenocarcinoma consistent with carcinoma in situ of the ovary. The above-mentioned cells were cultured in RPMI-1640 medium and McCoy’s 5A medium, respectively. 293T cells, which could continuously express SV40 antigen, was used in the transfection experiments with a high transfection efficiency, and was cultured in DMEM. The A2780 cell line was originally purchased from the European Collection of Authenticated Cell Cultures (ECACC; Cat. nos. 93112519). The SKOV3 and 293T cells were purchased from the American Type Culture Collection (ATCC; Cat. nos. HTB-77 and CRL-11268, respectively). All the culture media were supplemented with 10% fetal bovine serum (FBS). All these cells were cultured in a humidified incubator under standard culture conditions (37°C, 5% CO₂).

RNA isolation and reverse transcription-quantitative PCR (RT-qPCR). Total RNA from cells and tissues was isolated using TRIzol reagent (Invitrogen; Thermo Fisher Scientific) and cDNA was synthesized using the PrimeScript RT reagent kit (Takara). qPCR was performed using SYBR-Green qPCR master mix (Takara). The conditions for PCR included 3 stages: Hold stage (95°C, 30 sec), PCR stage for 40 cycles (95°C, 5 sec and 60°C, 34 sec), melt curve stage (95°C, 15 sec; 60°C, 1 min and 95°C, 15 sec). GAPDH served as the endogenous control. The primer sequences of PRC1 for RT-qPCR were as follows: Forward primer, ACACTCTGTGCGACGG AGTTAC; reverse primer, TTCGCCATCAAATCCTCAGTGGG. The primer sequences of GAPDH were as follows: Forward, AACAATTTGGATACGTTGGAAG and reverse, GCCATC ACGCCACAGTTTC. The method of quantification was relative quantification and ΔΔCq was calculated to analyze the relative gene expression (12).

Plasmid construction and lentivirus production. A lentivirus vector expressing shPRC1 (TRCN0000280715) was purchased from Sigma-Aldrich. siRNA was synthesized by the GenePharma. The sequences were as follows: PRC1, 5’-CGC UGUUUAUCUAACAGU-3’; forhead box protein M1 (FOXM1), 5’-GGACCUUUUUCGUUCAUCUUU-3’ and negative control (NC), 5’-UUCUUCGAACUGUGUCACGUdTdT-3’.

Lentivirus was produced in 293T cells packaged by pSAX2 and pMD2.G. The cells were infected with the 1 ml lentivirus liquid for 24 h in the presence of polybrene (8 μg/ml), and was selected with puromycin (2 μg/ml) for 1 week to acquire stable expressing cell lines. siRNA manipulation was performed in accordance with the instructions of the manufacturer of Lipofectamine 2000 (Invitrogen™). The time duration between transfection subsequence experiment was approximately 10-14 h.

MTT assay. 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) assay was firstly used to measure the proliferative ability of the A2780 cells subjected to PRC1 knockdown or overexpression compared to the cells transfected with empty plasmid. The A2780 cells were incubated in RPMI-1640 medium supplemented with 10% FBS, and were seeded in 96-well plates at concentrations of 1,000 cells per well. Cell proliferation was monitored at different time points (1-5 days). At fixed time points, 20 μl of MTT (Sigma-Aldrich) solution were added to each well. Following incubation for 4 h at 37°C, the supernatant was removed and 100 μl of DMSO (Sigma-Aldrich) were added to each well. The absorbance at 490 nm was evaluated using a microplate reader (Bio-Rad).

In addition, the changes in the IC₅₀ values of cisplatin, taxol and pegylated liposomal doxorubicin (LPD) were evaluated in the A2780 cells subjected to PRC1 knockdown or overexpression compared to the controls. The A2780 cells were seeded in 96-well plates at concentrations of 4,000 cells per well and were treated with gradually increasing concentrations of the drugs (as shown in Fig. 5C-F). Following incubation for 48 h at 37°C, 20 μl of MTT (Sigma-Aldrich) solution were added to each well. The remaining steps were the same as mentioned above.

 Colony formation assay. Colony formation assay was used to measure the proliferative ability of the A2780 cells subjected to PRC1 knockdown or overexpression compared to the controls. The A2780 cells were seeded in a 6-well plate with 1,000 cells per well, and cultured at 37°C for 10-14 days. Colonies were fixed with methanol for 15 min and stained with 0.5% crystal violet (Solarbio) for 20 min at room temperature. The number of colonies with ≥50 cells was counted under a microscope (IX71, Olympus).

Cell cycle analysis. Cell cycle analysis was performed to verify whether PRC1 regulates the cell cycle. The A2780 cells transfected with PRC1 siRNA and the controls were harvested and fixed with 75% ice-cold ethanol overnight at 4°C. Cell suspensions were stained with 1 ml propidium iodide stock solution (MultiSciences Lianke Biotech Co.) and analyzed using a FACScan flow cytometer (BD Biosciences).

Transwell assays. Transwell assay was performed to confirm whether RPC1 knockdown and overexpression affected...
the invasive and migratory abilities of the A2780 and SKOV3 cells. In addition, it was used to determine whether the silencing of PRC1 can reverse the FOXM1-mediated enhancement of the metastatic abilities of the A2780 cells. The cells were re-suspended in serum-free medium, and 200 µl suspension containing 1-2x10⁵ cells was seeded into the upper chambers, and 700 µl culture medium containing 20% fetal bovine serum was added to the lower compartment. The filter membrane of invasion assays was coated with diluted Matrigel (BD Biosciences). The cells that penetrated to the bottom were fixed with methanol and stained with 0.5% crystal violet (Solarbio) at room temperature for >30 min following incubation under standard culture conditions (37°C, 5% CO₂). The incubation times for the migration of the A2780 and SKOV3 cells were 24 and 10 h, and the times for invasion was 36 and 18 h, respectively. A light microscope (IX71, Olympus) was used to examine the cells and obtain images (x100 magnification).

**Wound healing assay.** To confirm whether PRC1 overexpression in A2780 cells facilitates the migratory ability compared with the control, a wound healing assay was performed. The A2780 cells were seeded in 24-well plate at 3.0x10⁵ per well. A 20 µl pipette tip was used to scratch a line when the cells reached 100% confluency as a monolayer. The cells were then cultured in serum-free medium. The distance between the two edges was monitored at 0 and 48 h following wound formation using a microscope (IX71, Olympus).

**Western blot analysis.** The fresh tissues and cells were lysed with RIPA buffer on ice. The BCA Protein Assay kit (Merck Millipore) was used to detect the protein concentration of the samples. The mass of protein loaded per lane was 50-90 µg. The sample proteins were separated by SDS-PAGE (separating gel, 10%; stacking gel, 5%) and electrotransferred onto a PVDF membrane (Merck Millipore). After blocking with 5% non-fat milk, the membrane was incubated overnight with primary antibodies at 4˚C followed by appropriate HRP-conjugated secondary antibodies for 2 h at room temperature the following day. The ECL system (GE Healthcare) was used to detect the protein bands, and β-actin was used as an endogenous control.

The primary antibodies in this study included: Anti-β-actin (1:5,000, F3022, Sigma-Aldrich), anti-PRC1 (1:500, ab51248, Abcam), anti-cyclin B1 (CCNB1; 1:1,000, ab32053, Abcam), anti-cyclin D1 (CCND1; 1:1,000, ab16663, Abcam), anti-Aurora B kinase (AURKB; 1:1,000, ab2254, Abcam), anti-p21 (1:1,000, ab109520, Abcam), anti-E-Cadherin (1:1,000, #3195, Cell Signaling Technology), anti-N-Cadherin (1:1,000, #13116, Cell Signaling Technology), anti-matrix metalloproteinase (MMP)9 (1:1,000, ab38898, Abcam), anti-Slug (1:1,000, ab27568, Abcam), anti-breast cancer 1 (BRCA1; 1:1,000, #9010, Cell Signaling Technology), anti-RAD51 (1:1,000, ab113534, Abcam), anti-poly(ADP-Ribose) polymerase 1 (PARP1; 1:1,000, ab32138, Abcam), anti-c-Myc (1:1,000, ab32072, Abcam) and anti-FOXM1 (1:1,000, ab207298, Abcam). The secondary antibodies were purchased from KPL. Anti-rabbit IgG (5220-0336) was diluted at 1:4,000 and anti-mouse IgG (5220-0341) was diluted at 1:6,000. ImageJ software (National Institutes of Health, 1.48v) was used to calculate the relative density.

**Immunohistochemical staining.** Immunohistochemical staining was performed in 210 cases of HGSOc and 42 normal cases. The primary antibodies in this study included: Anti-β-actin (1:5,000, F3022, Sigma-Aldrich), anti-PRC1 (1:500, ab51248, Abcam), anti-cyclin B1 (CCNB1; 1:1,000, ab32053, Abcam), anti-cyclin D1 (CCND1; 1:1,000, ab16663, Abcam), anti-Aurora B kinase (AURKB; 1:1,000, ab2254, Abcam), anti-p21 (1:1,000, ab109520, Abcam), anti-E-Cadherin (1:1,000, #3195, Cell Signaling Technology), anti-N-Cadherin (1:1,000, #13116, Cell Signaling Technology), anti-matrix metalloproteinase (MMP)9 (1:1,000, ab38898, Abcam), anti-Slug (1:1,000, ab27568, Abcam), anti-breast cancer 1 (BRCA1; 1:1,000, #9010, Cell Signaling Technology), anti-RAD51 (1:1,000, ab113534, Abcam), anti-poly(ADP-Ribose) polymerase 1 (PARP1; 1:1,000, ab32138, Abcam), anti-c-Myc (1:1,000, ab32072, Abcam) and anti-FOXM1 (1:1,000, ab207298, Abcam). The secondary antibodies were purchased from KPL. Anti-rabbit IgG (5220-0336) was diluted at 1:4,000 and anti-mouse IgG (5220-0341) was diluted at 1:6,000. ImageJ software (National Institutes of Health, 1.48v) was used to calculate the relative density.

### Table I. Association between PRC1 protein expression and the clinicopathological characteristics of patients with HGSOC.

| Characteristic          | No. of patients | PRC1 protein expression (n) | P-value |
|-------------------------|-----------------|-----------------------------|---------|
| Age (years)             |                 |                             |         |
| <55                     | 97              | 42                          | 55      | 0.333 |
| ≥55                     | 113             | 57                          | 56      |       |
| FIGO stage              |                 |                             |         |
| I-II                    | 38              | 21                          | 17      | 0.282 |
| III-IV                  | 172             | 77                          | 95      |       |
| CA-125                  |                 |                             |         |
| <500 U/ml               | 54              | 25                          | 29      | 0.870 |
| ≥500 U/ml              | 123             | 60                          | 63      |       |
| Ascites                 |                 |                             |         |
| <500 ml                | 72              | 33                          | 39      | 0.893 |
| ≥500 ml               | 126             | 59                          | 67      |       |
| Residual lesions        |                 |                             |         |
| <1 cm                   | 133             | 61                          | 72      | 0.567 |
| ≥1 cm                   | 77              | 32                          | 45      |       |
| Family history          |                 |                             |         |
| No                      | 161             | 74                          | 87      | 0.891 |
| Yes                     | 38              | 17                          | 21      |       |
| Platinum of first line  |                 |                             |         |
| Sensitive               | 87              | 40                          | 47      | 0.019
| Resistance              | 7               | 0                           | 7       |       |
| Platinum of second line |                 |                             |         |
| Sensitive               | 60              | 34                          | 29      | 0.028 |
| Resistance              | 21              | 7                           | 18      |       |
| Primary recurrence      |                 |                             |         |
| <6 months               | 24              | 8                           | 16      | 0.127 |
| ≥6 months               | 64              | 33                          | 31      |       |
| Secondary recurrence    |                 |                             |         |
| <6 months               | 16              | 5                           | 11      | 0.011
| ≥6 months               | 15              | 12                          | 3       |       |
| Three-year survival     |                 |                             |         |
| Alive                   | 89              | 55                          | 34      | 0.006
| Deceased                | 54              | 20                          | 34      |       |
| Five-year survival      |                 |                             |         |
| Alive                   | 72              | 47                          | 25      | 0.003
| Deceased                | 71              | 28                          | 43      |       |
| BRCA mutation status    |                 |                             |         |
| Pathogenic              | 17              | 13                          | 4       | 0.019
| Non-pathogenic          | 35              | 14                          | 21      |       |

*P<0.05; **P<0.01. PRC1, protein regulator of cytokinesis-1; HGSOc, high-grade serous ovarian carcinoma; BRCA, breast cancer susceptibility gene.
FT tissues to determine the expression and clinical significance of PRC1 in HGSOC. In addition, the immunohistochemical staining of PRC1 and FOXM1 in corresponding HGSOC samples was analyzed to verify the association between PRC1 and FOXM1. The TMAs were incubated at 60°C for 1 h, and subsequently deparaffinized in xylene and hydrated in a degraded series of ethanol. The heat-mediated antigen retrieval in EDTA buffer (pH 9.0), the inactivation of endogenous peroxidase activity and the blocking of non-specific antigens were then performed gradually. PRC1 antibody (1:100 dilution, HP034521, Sigma-Aldrich) was incubated with the slides at 4°C overnight followed by secondary antibodies (SP-9000, ZSBG-BIO) incubation for 20 min at room temperature. Then the sections were incubated with streptavidin-peroxidase for 15 min at room temperature. The staining was detected with the DAB detection system (Zhongshan Biotechnology Co.). Two investigators blinded to the clinical data evaluated the staining. Each sample had two duplicates and the average scores were used as the final result.

*Dual-luciferase reporter assay.* To determine whether FOXM1 can regulate the expression of PRC1 and identify the binding site, a dual-luciferase reporter assay was performed. The 293T cells were plated in 96-well plates and cultured for 24 h at 37°C, and transiently co-transfected with PCMV-FOXMIC (RC202540, Origene), PGL4.26-PRC1 (E8441, Promega) and pRL-TK (E2241, Promega) using Lipofectamine 2000. The luciferase activity was determined by the ratio of values between the addition of 75 µl lysis reagent and Firefly luminescence was measured after 10 min. The relative luciferase activity was determined using the Dual-Glo® Luciferase Assay System E2920 which was supplied by Promega. After 24 h, 75 µl fresh medium were added to the 96-well plates after the medium was removed. This was followed by the addition of 75 µl lysis reagent and Firefly luminescence was measured using a microplate reader (Bio-Rad) after 10 min. Subsequently, 75 µl Stop buffer were added to each well and the Renilla luminescence was measured after 10 min. The relative luciferase activity was determined by the ratio of values between Firefly luminescence and Renilla luminescence.

*BRCA mutation detection.* In order to verify whether PRC1 expression is associated with germline BRCA mutation, germline BRCA genetic testing was performed in 52 patients. Fresh blood of 6 ml was extracted and sequenced using the NGS platform from Shanghai Topgen Bio-pharm Co. Ltd. The BRCA1/2 panel (Morgen, China) was used which covers the entire coding sequences of BRCA1 and BRCA2, including 10-50 bases of adjacent intronic sequence of each exon. The variants were classified based on a highly accepted 5-class classification (13).

*Bioinformatics analyses.* Oncomine (www.oncomine.org) was used to visualize the differential expression of PRC1 in ovarian cancer and control samples. TCGA RNA expression data of ovarian serous cystadenocarcinoma were analyzed by the Cancer Genomics Browser (https://genome-cancer.ucsc.edu). Kaplan Meier-plotter (http://kmplot.com/analysis/) was used to analyze overall survival and the progression-free survival of patients as regards PRC1 expression in ovarian cancer. Gene regulation website (www.gene-regulation.com) was used to identify the promoter of PRC1. Pearson's correlation analysis was used to analyze the correlation of PRC1 and FOXM1 expression in TCGA cohort.

*Statistical analysis.* Statistical analysis was carried out using SPSS 23 software. The differences between continuous data were analyzed using a Student's t-test, and the comparisons between multiple groups were performed by one-way ANOVA, and Fishers' Least Significant Difference (LSD) was used as a post hoc test. The association between PRC1 expression and the clinical characteristics of the patients were analyzed using the Chi-square test. Multivariate cox regression analysis was used to analyze the association between clinical prognostic markers and overall survival. Overall survival analysis was performed by Kaplan-Meier and the log-rank test. A value of P<0.05 was considered to indicate a statistically significant difference.

**Results**

*PRC1 is overexpressed in HGSOC.* To determine the expression of PRC1 in HGSOC, the publicly accessible database Oncomine and TCGA cohort were employed to analyze PRC1 mRNA expression, and it was observed that PRC1 mRNA expression in serous ovarian carcinoma (SOC) was significantly higher compared with that in normal ovary tissues or normal peritoneum tissues (Fig. 1A-C). It was also found that the expression of PRC1 was positively associated with the malignancy of ovarian tumors (Fig. 1E and F). To confirm PRC1 overexpression in HGSOC, RT-qPCR was performed to measure PRC1 expression in normal FT (n=14) and HGSOC (n=28) tissues, and it was observed that the PRC1 mRNA level was significantly higher in HGSOC (Fig. 1D). Subsequently, western blot analysis was performed to determine the protein expression levels and the relative protein expression of PRC1 was calculated in normal FT (n=7) and HGSOC (n=8) tissues. The results obtained were similar to those for mRNA expression (Fig. 1G and H). All these results verified that PRC1 was markedly overexpressed in HGSOC tissues at both the mRNA and protein level, and suggested that PRC1 plays an important role in ovarian cancer development and biological characteristics.

*Association between PRC1 expression and clinicopathological parameters.* To further determine the expression and clinical significance of PRC1 in HGSOC, an immunohistochemistry assay was conducted to examine PRC1 protein expression in 210 HGSOC tissues and 42 normal FT tissues. As shown in Fig. 2E, PRC1 staining was mainly distributed in the cytoplasm, and the expression of the PRC1 was significantly upregulated in HGSOC tissues. To better understand the significance of PRC1 in HGSOC, the publicly accessible database Oncomine and TCGA cohort were employed to analyze PRC1 mRNA expression, and it was observed that PRC1 mRNA expression in serous ovarian carcinoma (SOC) was significantly higher compared with that in normal ovary tissues or normal peritoneum tissues (Fig. 1A-C). It was also found that the expression of PRC1 was positively associated with the malignancy of ovarian tumors (Fig. 1E and F). To confirm PRC1 overexpression in HGSOC, RT-qPCR was performed to measure PRC1 expression in normal FT (n=14) and HGSOC (n=28) tissues, and it was observed that the PRC1 mRNA level was significantly higher in HGSOC (Fig. 1D). Subsequently, western blot analysis was performed to determine the protein expression levels and the relative protein expression of PRC1 was calculated in normal FT (n=7) and HGSOC (n=8) tissues. The results obtained were similar to those for mRNA expression (Fig. 1G and H). All these results verified that PRC1 was markedly overexpressed in HGSOC tissues at both the mRNA and protein level, and suggested that PRC1 plays an important role in ovarian cancer development and biological characteristics.

To determine the expression and clinical significance of PRC1 in HGSOC tissues, the publicly accessible database Oncomine and TCGA cohort were employed to analyze PRC1 mRNA expression, and it was observed that PRC1 mRNA expression in serous ovarian carcinoma (SOC) was significantly higher compared with that in normal ovary tissues or normal peritoneum tissues (Fig. 1A-C). It was also found that the expression of PRC1 was positively associated with the malignancy of ovarian tumors (Fig. 1E and F). To confirm PRC1 overexpression in HGSOC, RT-qPCR was performed to measure PRC1 expression in normal FT (n=14) and HGSOC (n=28) tissues, and it was observed that the PRC1 mRNA level was significantly higher in HGSOC (Fig. 1D). Subsequently, western blot analysis was performed to determine the protein expression levels and the relative protein expression of PRC1 was calculated in normal FT (n=7) and HGSOC (n=8) tissues. The results obtained were similar to those for mRNA expression (Fig. 1G and H). All these results verified that PRC1 was markedly overexpressed in HGSOC tissues at both the mRNA and protein level, and suggested that PRC1 plays an important role in ovarian cancer development and biological characteristics.
recurrence interval and the mean recurrence interval were 12.1 vs. 10.2 months (P>0.05) and 7.3 vs. 4.9 months (P<0.05), respectively. In total, 52 cases of germline BRCA mutations were summarized; 17 cases were BRCA mutation carriers, and 13 of these 17 patients had a low expression of PRC1, with a P-value of 0.019 (Table I). However, no significant association was observed between the expression of PRC1 and the age of the patients, FIGO stage, the CA-125 level, ascites volume, residual lesions, family history and the primary recurrence interval (P>0.05). All the above-mentioned data confirmed that PRC1 played a major role in drug resistance and recurrence of HGSOC.

PRC1 contributes to a poor prognosis of patients with HGSOC. Kaplan Meier-plotter was used to investigate the effects of PRC1 expression on clinical prognosis, and the results revealed that the expression of PRC1 was negatively associated with the survival time (Fig. 2A-D). In total, 143 patients with HGSOC with complete survival information were analyzed to evaluate the importance of PRC1 overexpression in predicting HGSOC clinical outcomes according to immunohistochemical staining. It is found that patients with an elevated PRC1 expression had extremely significant poor outcomes in the 3-year survival rate, 5-year survival rate (Table I) and overall survival (Fig. 2F). Notably, multivariate Cox regression analysis revealed that a high expression of PRC1 protein was a unique independent prognostic factor for patients with HGSOC (Table II). These results provide evidence that a high expression of PRC1 indicates a worse prognosis of patients with HGSOC.

PRC1 promotes ovarian cancer cell proliferation in vitro. To evaluate the biological function of PRC1 in ovarian cancer, stable ovarian cancer cell lines with PRC1 overexpression and knockdown were established. The effect of PRC1 on the proliferative ability of the A2780 cells was then examined. Both growth curve analysis and colony formation assay demonstrated that PRC1 knockdown markedly inhibited cell growth and that PRC1 overexpression significantly enhanced cell proliferation (Fig. 3A and B). To further verify whether PRC1 regulates the cell cycle, PRC1 was knocked down in A2780 cells using siRNA and the changes in the cell cycle were then examined using fluorescence-activated cell sorting (FACS) analysis. As shown in Fig. 3E, PRC1 depletion significantly increased the percentage of cells in the G2 phase and decreased the percentage of cells in the G1 phase. In addition,
the results of western blot analysis revealed that the CCNB1, CCND1 and AURKB expression levels were decreased and p21 expression was increased following PRC1 knockdown, while the corresponding expression levels were reversed with PRC1 overexpression in A2780 cells (Fig. 3C and D). All these results suggested that PRC1 promoted ovarian cancer proliferation in vitro.

PRC1 promotes the migration and invasion of ovarian cancer cells in vitro. A wound healing assay was first performed to determine the effects of PRC1 expression on the metastasis of ovarian cancer cells, and the results revealed that PRC1 overexpression in A2780 cells significantly facilitated the migratory ability of the cells compared with the control (Fig. 4E). Transwell assay also revealed that the migratory and invasive ability of the cells was significantly inhibited in the PRC1-depleted cells; on the contrary however, the metastatic ability was enhanced in the PRC1-overexpressing cells (Fig. 4A and B). Finally, the levels of epithelial-mesenchymal transition (EMT) markers were measured by western blot analysis, as shown in Fig. 4C and D. The expression of E-Cadherin, N-Cadherin, MMP9 and Slug was decreased following PRC1 knockdown. Taken together, all these data suggest an important role of PRC1 in the migratory and invasive ability of ovarian cancer cells via EMT.

PRC1 promotes the multi-drug resistance of ovarian cancer cells in vitro. Immunohistochemical staining was first applied
Figure 3. PRC1 increases the proliferative ability of ovarian cancer cells in vitro. (A and B) Clonogenic assay and growth curve assay were used to examine the effects of PRC1 on the proliferation of ovarian cancer cells. (C and D) Cell cycle-related proteins and the corresponding densitometric analysis in A2780 cells with PRC1 knockdown and overexpression examined by western blot analysis. (E) Cell cycle analysis of PRC1 knockdown in A2780 cells compared with the control cells analyzed by flow cytometry. *P<0.05 and **P<0.01. PRC1, protein regulator of cytokinesis-1.

Figure 4. PRC1 promotes the migration and invasion of ovarian cancer cells in vitro. (A and B) Effects of PRC1 on the migratory and invasive ability of ovarian cancer cells with PRC1 overexpression or knockdown. (C and D) Western blot analysis of EMT-associated markers and the corresponding densitometric analysis in PRC1 knockdown A2780 and SKOV3 cells compared with the control cells. (E) Wound healing assay was used to assess the cell motility in PRC1-overexpressing A2780 cells compared to the control cells. *P<0.05 and **P<0.01. PRC1, protein regulator of cytokinesis-1; EMT, epithelial-mesenchymal transition; MMP9, matrix metalloproteinase 9.
to examine the expression of PRC1 in HGSOC samples with second-line treatment. As shown in Fig. 5A, the expression of PRC1 in the resistant samples was higher than in the sensitive ones. In total, 38.3% (18/47) patients with a high expression of PRC1 were resistant to platinum-based chemotherapy, while only 17.1% (7/41) of patients with a low expression of PRC1 were resistant (Table I). The mRNA expression level of PRC1 in the partial samples with second-line treatment described above was further investigated; it was found that 10 patients were sensitive to platinum, 8 were platinum-resistant, and the expression of PRC1 was evidently higher in the samples of resistant patients (Fig. 5B). Finally, MTT assay was performed to evaluate the changes in the IC$_{50}$ values of cisplatin, taxol and LPD in PRC1 knockdown and overexpression cells. The results confirmed that PRC1 played an important role in the drug resistance of ovarian cancer.

**FOXM1 activates the expression of PRC1 through binding to its promoter directly.**

The promoter of PRC1 was analyzed using a gene regulation website (www.gene-regulation.com), and it was found that a number of transcription factors could bind to its promoter, including FOXM1. The expression of PRC1 was found to positively correlate with the expression of FOXM1 in the TCGA cohort analysis (Fig. 6B). It was found that the expression of PRC1 was markedly decreased at both the mRNA and protein level following FOXM1 knockdown (Fig. 6C-E). The results of immunohistochemical staining of corresponding HGSOC samples revealed that the expression of PRC1 was consistent with the expression of FOXM1 (Fig. 6A). The results of luciferase reporter assay revealed that FOXM1 activated the expression of PRC1 by directly binding to the promoter of PRC1 and PRC1 luciferase activity was decreased when the binding site was mutated (Fig. 6F and G). To determine these results confirmed that PRC1 played an important role in the drug resistance of ovarian cancer.
whether PRC1 serves as a downstream target of FOXM1, PRC1 was knocked down in FOXM1-overexpressing cells. Transwell assay was then used to determine whether the silencing of PRC1 could reverse the FOXM1-mediated increase in the metastatic ability of A2780 cells. As shown in Fig. 6H and I, the silencing of PRC1 inhibited the FOXM1-mediated promotion of the migratory and invasive ability of the ovarian cancer cells. These results thus suggested that the overexpression of PRC1 was ascribed from the regulation of FOXM1, and it may serve as an important executor.

Discussion

Although ovarian cancer is not the most common malignant tumor of gynecological cancers, it is the most lethal, and despite advances being made in surgical and chemotherapy management, ovarian cancer mortality has remained virtually unaffected (14,15). PARP inhibitors targeting BRCA pathogenic mutations are the only major breakthrough made in the treatment of ovarian cancer in recent decades; however, only approximately 20% of patients can benefit from
these (16). At present, there is still no systematic mechanism for the pathogenesis, metastasis, drug-resistance mechanisms of ovarian cancer. In this study, it was verified that PRC1 was significantly overexpressed in HGSOC, particularly in patients without BRCA pathogenic mutations, and that its overexpression was strongly associated with the sensitivity of platinum-based chemotherapy and poor prognosis of patients. In addition, we further demonstrated that PRC1 was essential for the function of ovarian cancer cells. As a key target gene of FOXM1, PRC1 is expected to be a novel therapeutic target of ovarian cancers, particularly for patients without BRCA pathogenic mutations.

EMT is a process through which epithelial cells lose cell polarity and homogenous adhesion, and gain migratory and invasive properties (35). In recent studies, EMT has been confirmed to significantly reduce the survival of ovarian cancer patients (51). In this study, it was confirmed that PRC1 was associated with metastasis in vitro, there was no significant difference found in the FIGO stage, and this may be related to the failure of the early diagnosis of ovarian cancer. All these results suggest that PRC1 may prove to be a therapeutic target with great potential.

FOXMI is a tumorigenic transcription factor of the forkhead family, and has been confirmed to play a crucial role in the proliferation and progression of multiple tumor cells. FOXMI is overexpressed in >20 human tumors and promotes tumor cell proliferation, invasion, metastasis and the chemo-resistant processes of ovarian cancers (46-50). In addition, the overexpression of FOXMI has been shown to significantly reduce the survival of ovarian cancer patients (51). In this study, it was confirmed that PRC1 was a direct downstream gene of FOXMI via mRNA and protein expression verification and luciferase assay. Furthermore, this study demonstrated that the silencing PRC1 inhibited the invasive and migratory ability of FOXM1-overexpressing ovarian cancer cells.

In conclusion, this study verified the expression pattern, molecular mechanisms and clinical information of PRC1 in HGSOC, and confirmed that the upregulated expression of PRC1 enhanced the proliferation, invasion, migration and multi-drug resistance of ovarian cancer cells in vitro. Clinical data analysis also confirmed the key role of PRC1 in tumor resistance, recurrence and a poor prognosis. The study thus indicated that PRC1 may prove to be a promising molecular target for ovarian cancer, and small molecule inhibitors targeting PRC1 may have desirable anticancer effects.

Acknowledgements

Not applicable.

Funding

This study was supported by the National Natural Science Foundation of China (grant nos. 81874107, 81572554 and 81572559), and the Program for Interdisciplinary Basic Research of Shandong University (grant no. 2018JC014).

Availability of data and materials

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.
Authors' contributions

HB and YL contributed to the experimental work, figures and drafting of the manuscript. CJ made substantial contributions to the design of the study and data analysis. HY, XW assisted with the experiments and data analysis. JC, YW and YM assisted with acquisition and analysis of clinical information. YZ and BK designed and supervised all the experiments. All authors have read and approved the final manuscript.

Ethics approval and consent to participate

Ethics approval was obtained from the Ethics Committee of Shandong University, and written informed consent was obtained from each patient.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68: 394-424, 2018.
2. Siegel RL, Miller KD and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62: 10-29, 2012.
3. Nik NN, Vang R, Shih Ie M and Kurman RJ: Origin and pathogenesis of pelvic (ovarian, tubal, and primary peritoneal) serous carcinoma. Annu Rev Pathol 9: 27-45, 2014.
4. Jiang W, Jimenez G, Wells NJ, Hope TJ, Wahl GM, Hunter T and Fukunaga R: PRC1: A human mitotic spindle-associated CDK substrate protein required for cytokinesis. Mol Cell 2: 877-885, 1998.
5. Mallinari C, Klenan JP, Jiang W, Schoen G, Hunter T and Marvylis RL: PRC1 is a microtubule binding and bundling protein essential to maintain the mitotic spindle midzone. J Cell Biol 157: 1175-1186, 2002.
6. Karasawa Y, Earnshaw WC, Mochizuki Y, Dohmae N and Todokoro K: Essential roles of KIF4 and its binding partner PRC1 in organized central spindle midzone formation. EMBO J 23: 3237-3248, 2004.
7. Chen J, Rajaskaran M, Xia H, Zhang X, Kong SN, Sekar K, Seshachalam VP, Deivaigamani A, Goh BK, Ooi LL, et al: The microtubule-associated protein PRC1 promotes early recurrence of hepatocellular carcinoma in association with the Wnt-β-catenin signalling pathway. Gut 65: 1522-1534, 2016.
8. Zhang B, Shi X, Xu G, Kang W, Zhang W, Zhang S, Cao Y, Qian L, Zhan P, Yan H, et al: Elevated PRC1 in gastric carcinoma exerts oncogenic function and is targeted by piperlongumine in a p53-dependent manner. J Cell Mol Med 21: 1329-1341, 2017.
9. Zhan P, Xi GM, Liu HB, Liu YF, Xu WJ, Zhu Q, Zhou ZJ, Miao YY, Wang XX, Jin JJ, et al: Protein regulator of cytokinesis-1 expression: Prognostic value in lung squamous cell carcinoma patients. J Thorac Dis 9: 2054-2060, 2017.
10. Zhan P, Zhang B, Xi G, Wu Y, Liu HB, Liu YF, Xu WJ, Zhu QQ, Cai F, Zhou ZJ, et al: PRC1 contributes to tumorgenesis of lung adenocarcinoma in association with the Wnt-β-catenin signaling pathway. Mol Cancer 16: 108, 2017.
11. Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, du Bois A, Kristensen G, Jakobsen A, Sague S, et al: Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer 21: 419-423, 2011.
12. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2-(ΔΔCT) method. Methods 25: 402-408, 2001.
13. Plon SE, Eccles DM, Easton D, Foulkes WD, Genuardi M, Greenblatt MS, Hogervorst FB, Hoogerbrugge N, Spurdle AB and Tavtigian SV: IARC Unclassified Genetic Variants Working Group: Sequencing: Validation and reporting: Recommendations for improving the interpretation of BRCA1 and BRCA2 susceptibility genetic test results. Hum Mutat 29: 1282-1291, 2008.
14. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin 65: 87-108, 2015.
15. Vaughan S, Coward J, Bast RC Jr, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, et al: Rethinking ovarian cancer: Recommendations for improving outcomes. Nat Rev Cancer 11: 719-725, 2011.
16. Shi T, Wang P, Xie C, Yin S, Shi D, Wei C, Tang W, Jiang R, Cheng X, Wei Q, et al: BRCA1 and BRCA2 mutations in ovarian cancer patients from China: Ethnic-related mutations in BRCA1 associated with an increased risk of ovarian cancer. Int J Cancer 140: 2051-2059, 2017.
17. Fujiwara T, Bandi M, Nitta M, Ivanova EV, Bronston RT and Pellman D: Cytokinesis failure generating tetraploids promotes tumorigenesis in p53-null cells. Nature 457: 1043-1047, 2005.
18. Steinemann P, Wurzenberger C, Schmitz MH, Held M, Guizetti J, Maar S and Gerlich DW: Aurora-B mediated abscess-formation checkpoint protects against tetraploidization. Cell 136: 473-484, 2009.
19. Zhang Y, Jiang C, Li H, Lv F, Li X, Qian X, Fu L, Xu B and Guo X: Elevated Aurora B expression contributes to chemoresistance and poor prognosis in breast cancer. Int J Clin Exp Pathol 8: 751-757, 2015.
20. Hetland TE, Nyemoen DA, Holth A, Brusegard K, Florenes VA, Kjærn J, Tropé CG and Davidson B: Aurora B expression in metastatic effusions from advanced-stage ovarian serous carcinoma is predictive of intrinsic chemoresistance therapy. Hum Pathol 44: 777-785, 2013.
21. Beussel S, Hasenburg A, Bogatyreva L, Hauschke D, Wernher M and Lassmann S: Aurora-B protein expression is linked to initial response to taxane-based first-line chemotherapy in stage III ovarian carcinoma. J Clin Pathol 65: 29-35, 2012.
22. Davidson B, Nyemoen DA, Elgaen BV, Staff AC, Tropé CG, Kjærn J, Reich R and Falkeholt TE: BUB1 mRNA is significantly co-expressed with AURKA and AURKB mRNA in advanced-stage ovarian serous carcinoma. Virchows Arch 464: 701-707, 2014.
23. Chen YJ, Chen CM, Twu NF, Yen MS, Lai CR, Wu HH, Wang PH and Yuen CC: Overexpression of Aurora B is associated with poor prognosis in epithelial ovarian cancer patients. Virchows Arch 455: 431-440, 2009.
24. Honma K, Nakashiki R, Nakano TK, Ando K, Oki E, Nishimori M, Kitao H, Kakeji Y and Maehara Y: Contribution of Aurora-A and -B expression to DNA aneuploidy in gastric cancers. Surg Today 44: 454-461, 2014.
25. Tuncel S, Shimamoto F, Kaneko Guangying Qi H, Aoki E, Kijihara H, Nakai S, Takata T and Tatsuka M: Nuclear Aurora B and cytoplasmic Survivin expression is involved in lymph node metastasis of colorectal cancer. Oncol Lett 3: 1109-1114, 2012.
26. Takeshita M, Koga T, Takayama K, Iijichi K, Yano T, Maehara Y, Nakanihshi Y and Sueishi K: Aurora-B overexpression is correlated with aneuploidy and poor prognosis in non-small cell lung cancer. Lung Cancer 80: 85-90, 2013.
27. Fadri-Moskwik M, Weiderholm KN, Deeraaska A, Chuan C, Pan CL, Lin SH and Yu-Lee LY: Aurora B is regulated by acetylation/deacetylation during mitosis in prostate cancer cells. FASEB J 26: 4057-4067, 2012.
28. Premkumar DR, Jane EP and Pollack IF: Cucurbitacin-I inhibits Aurora kinase A, Aurora kinase B and survivin, induces defects in cell cycle progression and promotes ABT-737-induced cell death in a caspase-independent manner in malignant human glioma cells. Cancer Biol Ther 16: 233-243, 2015.
29. Diaz RJ, Golbourn B, Shekarforoush M, Smith CA and Rutka JT: Aurora kinase B/C inhibition impairs malignant glioma growth in vivo. J Neurooncol 119: 340-342, 2013.
30. Cancer Genome Atlas Research Network: Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615, 2011.
Prathapam T, Aleshin A, Guan Y, Gray JW and Martin GS: p27Kip1 mediates addiction of ovarian cancer cells to MYCC (c-MYC) and their dependence on MYC paralogs. J Biol Chem 285: 32529-32538, 2010.

Reyes-Gonzalez JM, Armaiz-Peña GN, Mangala LS, Valiyeva F, Ivan C, Pradeep S, Echevarría-Vargas IM, Rivera-Reyes A, Sood AK and Vivas-Mejía PE: Targeting c-MYC in platinum-resistant ovarian cancer. Mol Cancer Ther 14: 2260-2269, 2015.

Kalluri R and Weinberg RA: The basics of epithelial-mesenchymal transition. J Clin Invest 119: 1420-1428, 2009.

Zhang Y, Zeng S, Ma J, Deng G, Qu Y, Guo C and Shen H: Nestin overexpression in hepatocellular carcinoma associates with epithelial-mesenchymal transition and chemoresistance. J Exp Clin Cancer Res 35: 111, 2016.